{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:35:36Z","timestamp":1794468936890,"version":"4.9.1"},"reference-count":204,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The first international guidance on antithrombotic therapy in the elderly came from the European Society of Cardiology Working Group on Thrombosis in 2015. This same group has updated its previous report on antiplatelet and anticoagulant drugs for older patients with acute or chronic coronary syndromes, atrial fibrillation, or undergoing surgery or procedures typical of the elderly (transcatheter aortic valve implantation and left atrial appendage closure). The aim is to provide a succinct but comprehensive tool for readers to understand the bases of antithrombotic therapy in older patients, despite the complexities of comorbidities, comedications and uncertain ischaemic- vs. bleeding-risk balance. Fourteen updated consensus statements integrate recent trial data and other evidence, with a focus on high bleeding risk. Guideline recommendations, when present, are highlighted, as well as gaps in evidence. Key consensus points include efforts to improve medical adherence through deprescribing and polypill use; adoption of universal risk definitions for bleeding, myocardial infarction, stroke and cause-specific death; multiple bleeding-avoidance strategies, ranging from gastroprotection with aspirin use to selection of antithrombotic-drug composition, dosing and duration tailored to multiple variables (setting, history, overall risk, age, weight, renal function, comedications, procedures) that need special consideration when managing older adults.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehac515","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T16:47:22Z","timestamp":1662655642000},"page":"262-279","source":"Crossref","is-referenced-by-count":61,"title":["Acute, periprocedural and longterm antithrombotic therapy in older adults"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-6430","authenticated-orcid":false,"given":"Felicita","family":"Andreotti","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Gemelli IRCCS , Largo F Vito 1, 00168 Rome ,","place":["Italy"]},{"name":"Department of Cardiovascular and Pneumological Sciences, Catholic University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-6038","authenticated-orcid":false,"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, University Hospital, Eberhard-Karls-University Tuebingen , Otfried-M\u00fcller-Stra\u00dfe 10, 72076 Tuebingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-5347","authenticated-orcid":false,"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[{"name":"Paris Sorbonne Universit\u00e9 (UPMC), ACTION Study Group, INSERM UMR_S 1166, Institut de Cardiologie, Piti\u00e9-Salp\u00eatri\u00e8re Hospital (AP-HP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Gigante","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Karolinska Institutet and Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A","family":"Gorog","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College , London ,","place":["UK"]},{"name":"Postgraduate Medical School, University of Hertfordshire , Hertfordshire ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Ulleval, University of Oslo , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Cardiologia, Centro Hospitalar de Leiria and Center for Innovative Care and Health Technology (ciTechCare), Leiria Polytechnic Institute , Leiria ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliano Pio","family":"Navarese","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Collegium Medicum, Nicolaus Copernicus University , Bydgoszcz ,","place":["Poland"]},{"name":"SIRIO MEDICINE Network and Faculty of Medicine University of Alberta , Edmonton ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6447-2424","authenticated-orcid":false,"given":"Carlo","family":"Patrono","sequence":"additional","affiliation":[{"name":"Department of Safety and Bioethics, Section on Pharmacology, Catholic University School of Medicine , Rome ,","place":["Italy"]},{"name":"Fondazione Policlinico Universitario Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Safety and Bioethics, Section on Pharmacology, Catholic University School of Medicine , Rome ,","place":["Italy"]},{"name":"Fondazione Policlinico Universitario Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Cardiovascular Diseases\u2014AUSL Romagna, S. Maria delle Croci Hospital , Ravenna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0698-2696","authenticated-orcid":false,"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[{"name":"Privatklinik Lauterbacher M\u00fchle am Ostersee, Seeshaupt, Germany & Ludwig-Maximilians-Universit\u00e4t (LMU) M\u00fcnchen , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W A","family":"Verheugt","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heartcenter, Onze Lieve Vrouwe Gasthuis (OLVG) , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Vilahur","sequence":"additional","affiliation":[{"name":"Cardiovascular Program-ICCC, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau , Barcelona ,","place":["Spain"]},{"name":"CIBERCV, Instituto Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"2024121216125244600_ehac515-B1"},{"key":"2024121216125244600_ehac515-B2"},{"key":"2024121216125244600_ehac515-B3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/gerona\/gly110","article-title":"Frailty and multimorbidity: a systematic review and meta-analysis","volume":"74","author":"Vetrano","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2024121216125244600_ehac515-B4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(19)32007-0","article-title":"Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study","volume":"395","author":"Dagenais","year":"2020","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2012.14312","article-title":"Lifetime risk and years lived free of total cardiovascular disease","volume":"308","author":"Wilkins","year":"2012","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B6","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2015.07.026","article-title":"Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan","volume":"66","author":"Chao","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B7","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B9","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2018.03.459","article-title":"Valvular heart disease in patients \u226580 years of age","volume":"71","author":"Kodali","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.surg.2017.09.035","article-title":"The impact of the aging population and incidence of cancer on future projections of general surgical workforce needs","volume":"163","author":"Ellison","year":"2018","journal-title":"Surgery"},{"key":"2024121216125244600_ehac515-B11","first-page":"3238","article-title":"Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B12","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2018.8194","article-title":"Annual risk of major bleeding among persons without cardiovascular disease not receiving antiplatelet therapy","volume":"319","author":"Selak","year":"2018","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B13","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: its importance in cardiovascular outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"2024121216125244600_ehac515-B15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40266-014-0163-7","article-title":"Medication non-adherence among elderly patients newly discharged and receiving polypharmacy","volume":"31","author":"Pasina","year":"2014","journal-title":"Drugs Aging"},{"key":"2024121216125244600_ehac515-B16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000450750","article-title":"Frequency and determinants of adherence to oral anticoagulants in stroke patients with atrial fibrillation in clinical practice","volume":"76","author":"Polymeris","year":"2016","journal-title":"Eur Neurol"},{"key":"2024121216125244600_ehac515-B17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12913-022-07483-8","article-title":"Effects of medicare comprehensive medication review on racial\/ethnic disparities in nonadherence to statin medications among patients with Alzheimer\u2019s disease: an observational analysis","volume":"22","author":"Browning","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"2024121216125244600_ehac515-B18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bcp.12975","article-title":"The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis","volume":"82","author":"Page","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2024121216125244600_ehac515-B19","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0140-6736(17)30553-6","article-title":"Uses of polypills for cardiovascular disease and evidence to date","volume":"389","author":"Huffman","year":"2017","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B20","article-title":"Interventions to improve the appropriate use of polypharmacy for older people.","volume":"9","author":"Rankin","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2024121216125244600_ehac515-B21","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","article-title":"Deprescribing in older adults with cardiovascular disease","volume":"73","author":"Krishnaswami","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B22","article-title":"Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases","volume":"2017","author":"Bahiru","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2024121216125244600_ehac515-B23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis","volume":"398","author":"Joseph","year":"2021","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B25","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1055\/s-0038-1635259","article-title":"Prediction of post-discharge bleeding in elderly patients with acute coronary syndromes: insights from the BleeMACS registry","volume":"118","author":"Garay","year":"2018","journal-title":"Thromb Haemost"},{"key":"2024121216125244600_ehac515-B28","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B29","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients","volume":"75","author":"Cao","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2019","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B33","doi-asserted-by":"crossref","first-page":"e020974","DOI":"10.1161\/JAHA.121.020974","article-title":"Validation of the 4-item PRECISE-DAPT score: a SWEDEHEART study","volume":"10","author":"Wester","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024121216125244600_ehac515-B34","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jcin.2021.01.007","article-title":"Assessment of the Academic Research Consortium for high bleeding risk criteria in patients undergoing TAVR","volume":"14","author":"Bor","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B35","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jcin.2021.03.024","article-title":"Development and validation of a practical model to identify patients at risk of bleeding after TAVR","volume":"14","author":"Navarese","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B36","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/eurheartj\/ehy066","article-title":"Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis","volume":"39","author":"Rocca","year":"2018","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B37","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B38","doi-asserted-by":"crossref","first-page":"e005657","DOI":"10.1161\/JAHA.117.005657","article-title":"Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PRE vention oF Thromboembolic Events\u2013 European Registry in Atrial Fibrillation)","volume":"6","author":"Patti","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2024121216125244600_ehac515-B39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/europace\/euz345","article-title":"Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention\/acute coronary syndrome patients","volume":"22","author":"Galli","year":"2020","journal-title":"Europace"},{"key":"2024121216125244600_ehac515-B40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B42","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.5551\/jat.62999","article-title":"Practical assessment of the tradeoff between fatal bleeding and coronary thrombotic risks using the academic research consortium for high bleeding risk criteria","volume":"29","author":"Sotomi","year":"2022","journal-title":"J Atheroscler Thromb"},{"key":"2024121216125244600_ehac515-B43","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamacardio.2020.6814","article-title":"Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC-high bleeding risk trade-off model","volume":"6","author":"Urban","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2024121216125244600_ehac515-B44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2024121216125244600_ehac515-B45","first-page":"1455","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis","volume":"38","author":"Halvorsen","year":"2016","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials","volume":"3","author":"Scally","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024121216125244600_ehac515-B47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"2024121216125244600_ehac515-B48","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B49","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury","volume":"79","author":"Han","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B51","doi-asserted-by":"crossref","first-page":"e1605","DOI":"10.4244\/EIJ-D-19-00699","article-title":"Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients aged above 75 years: a prespecified analysis of the randomized GLOBAL LEADERS trial","volume":"15","author":"Tomaniak","year":"2020","journal-title":"EuroIntervention"},{"key":"2024121216125244600_ehac515-B52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B53","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B54","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B55","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40256-018-0313-0","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: subanalysis of a randomized clinical trial (JPPP-70)","volume":"19","author":"Sugawara","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"2024121216125244600_ehac515-B57","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology Working Group on Thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B59","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","article-title":"Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD","volume":"73","author":"Arora","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B60","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/jth.14776","article-title":"Contribution of exome sequencing to the identification of genes involved in the response to clopidogrel in cardiovascular patients","volume":"18","author":"Fontana","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2024121216125244600_ehac515-B61","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jacc.2013.05.023","article-title":"Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients","volume":"62","author":"Erlinge","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B62","first-page":"41","article-title":"Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis","volume":"25","author":"Denninger","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"2024121216125244600_ehac515-B63","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/phar.1477","article-title":"Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety","volume":"34","author":"Dobesh","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2024121216125244600_ehac515-B64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11630960-000000000-00000","article-title":"Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor","volume":"51","author":"Teng","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"2024121216125244600_ehac515-B65","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B66","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B67","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.964395","article-title":"Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient outcomes (PLATO) trial","volume":"5","author":"Husted","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2024121216125244600_ehac515-B68","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B69","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.120.050645","article-title":"Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry","volume":"142","author":"Szummer","year":"2020","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B70","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.117.032180","article-title":"Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization","volume":"137","author":"Savonitto","year":"2018","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B71","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.113.002303","article-title":"Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel","volume":"128","author":"Roe","year":"2013","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B72","doi-asserted-by":"crossref","first-page":"436","DOI":"10.7326\/M20-1806","article-title":"Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes: results from a randomized trial","volume":"173","author":"Menichelli","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024121216125244600_ehac515-B73","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B74","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials","volume":"142","author":"Navarese","year":"2020","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B75","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B76","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B77","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B78","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B79","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B80","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial","volume":"67","author":"Storey","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B81","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1161\/STROKEAHA.120.031755","article-title":"Balancing benefits and risks of long-term antiplatelet therapy in noncardioembolic transient ischemic attack or stroke","volume":"52","author":"Hilkens","year":"2021","journal-title":"Stroke"},{"key":"2024121216125244600_ehac515-B82","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.117.031658","article-title":"Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study","volume":"138","author":"Chao","year":"2018","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/ageing\/afx103","article-title":"Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis","volume":"47","author":"Bai","year":"2018","journal-title":"Age Ageing"},{"key":"2024121216125244600_ehac515-B85","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jgs.12799","article-title":"New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials","volume":"62","author":"Sardar","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"2024121216125244600_ehac515-B86","doi-asserted-by":"crossref","first-page":"f20","DOI":"10.1093\/ehjcvp\/pvz073","article-title":"Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients","volume":"7","author":"Silverio","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024121216125244600_ehac515-B87","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fcvm.2020.00132","article-title":"Direct oral anticoagulants vs. vitamin-K antagonists in the elderly with atrial fibrillation: a systematic review comparing benefits and harms between observational studies and randomized controlled trials","volume":"7","author":"Shen","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2024121216125244600_ehac515-B88","first-page":"105","article-title":"Polytherapy and drug interactions in elderly","volume":"7","author":"Gujjarlamudi","year":"2016","journal-title":"J Midlife Health"},{"key":"2024121216125244600_ehac515-B89","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B90","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B91","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients","volume":"63","author":"Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B92"},{"key":"2024121216125244600_ehac515-B93","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2024121216125244600_ehac515-B94","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B95","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40262-016-0417-0","article-title":"Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study","volume":"56","author":"Glund","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2024121216125244600_ehac515-B96","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B97","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B98","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B99","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B100","doi-asserted-by":"crossref","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF\u2013TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2024121216125244600_ehac515-B101","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B102","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.archger.2018.12.013","article-title":"Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis","volume":"81","author":"Caldeira","year":"2019","journal-title":"Arch Gerontol Geriatr"},{"key":"2024121216125244600_ehac515-B103","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B104","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin","volume":"63","author":"Hylek","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B105","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B106","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/eurheartj\/ehab637","article-title":"Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects","volume":"43","author":"Ansell","year":"2022","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B107","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B108","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B109","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B110","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B111","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B112","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B113","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B114","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2024121216125244600_ehac515-B115","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B116","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1093\/eurheartj\/ehab702","article-title":"Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR","volume":"42","author":"Escaned","year":"2021","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B117","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","article-title":"Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. Prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B118","doi-asserted-by":"crossref","first-page":"e022700","DOI":"10.1161\/JAHA.121.022700","article-title":"Age-dependent effect of ticagrelor monotherapy versus ticagrelor with aspirin on major bleeding and cardiovascular events: a post hoc analysis of the TICO randomized trial","volume":"10","author":"Kim","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024121216125244600_ehac515-B119","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1093\/eurheartj\/ehy332","article-title":"Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial","volume":"39","author":"Sibbing","year":"2018","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B120","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B121","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B122","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B123","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/eurheartj\/ehz404","article-title":"Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial","volume":"40","author":"de Vries","year":"2019","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/clc.23505","article-title":"Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry","volume":"44","author":"Darmon","year":"2020","journal-title":"Clin Cardiol"},{"key":"2024121216125244600_ehac515-B125","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1093\/eurheartj\/ehab408","article-title":"Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial","volume":"42","author":"Krantz","year":"2021","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B126","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B127","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2024121216125244600_ehac515-B128","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1161\/CIRCULATIONAHA.119.043308","article-title":"Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial","volume":"140","author":"Windecker","year":"2019","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/ehjcvp\/pvaa003","article-title":"Algorithm for the management of antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: an updated proposal based on efficacy considerations","volume":"6","author":"Rubboli","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024121216125244600_ehac515-B130","doi-asserted-by":"crossref","first-page":"f50","DOI":"10.1093\/ehjcvp\/pvaa116","article-title":"Safety and efficacy of double vs. Triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"7","author":"Gargiulo","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024121216125244600_ehac515-B131","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"2024121216125244600_ehac515-B132","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a north American perspective\u20132018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B133","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B134","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B135","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation: OAC-ALONE study","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B136","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B137","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B138","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B139","doi-asserted-by":"crossref","first-page":"pii: e005257","DOI":"10.1161\/CIRCINTERVENTIONS.117.005257","article-title":"Cangrelor in older patients undergoing percutaneous coronary intervention: findings from CHAMPION PHOENIX","volume":"10","author":"Cavender","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B140","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B141","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1570161116666180117102422","article-title":"What is the role for glycoprotein IIB\/IIIA inhibitor use in the catheterization laboratory in the current era?","volume":"16","author":"Rubboli","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"2024121216125244600_ehac515-B142","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/0003319716629541","article-title":"Intravenous enoxaparin versus unfractionated heparin in elderly patients undergoing primary percutaneous coronary intervention: an analysis of the randomized ATOLL trial","volume":"68","author":"Liu","year":"2017","journal-title":"Angiology"},{"key":"2024121216125244600_ehac515-B143","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B144","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B145","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.2015.517","article-title":"Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non\u2013ST-segment elevation myocardial infarction","volume":"313","author":"Szummer","year":"2015","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B146","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.108.789479","article-title":"Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials","volume":"118","author":"Mehta","year":"2008","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B147"},{"key":"2024121216125244600_ehac515-B148"},{"key":"2024121216125244600_ehac515-B149","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcin.2014.10.003","article-title":"Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb\/IIIa inhibitors in patients with acute coronary syndrome","volume":"8","author":"Navarese","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B150","doi-asserted-by":"crossref","first-page":"e008671","DOI":"10.1161\/CIRCINTERVENTIONS.119.008671","article-title":"Bivalirudin versus heparin monotherapy in elderly patients with myocardial infarction: a prespecified subgroup analysis of the VALIDATE-SWEDEHEART trial","volume":"13","author":"Wester","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B151","doi-asserted-by":"crossref","first-page":"e003515","DOI":"10.1161\/JAHA.116.003515","article-title":"Prolonged high-dose bivalirudin infusion reduces major bleeding without increasing stent thrombosis in patients undergoing primary percutaneous coronary intervention: novel insights from an updated meta-analysis","volume":"5","author":"Fahrni","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2024121216125244600_ehac515-B152","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(94)91161-4","article-title":"Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients","volume":"343","author":"Fibrinolytic Therapy Trialists\u2019 (FTT) Collaborative Group","year":"1994","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","article-title":"Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials","volume":"361","author":"Keeley","year":"2003","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B154","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/eurheartj\/ehq375","article-title":"Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies","volume":"32","author":"Bueno","year":"2011","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B155","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa1301092","article-title":"Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction","volume":"368","author":"Armstrong","year":"2013","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B156","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(05)80089-3","article-title":"Individual risk assessment for intracranial haemorrhage during thrombolytic therapy","volume":"342","author":"Simoons","year":"1993","journal-title":"Lancet"},{"key":"2024121216125244600_ehac515-B157","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/eurheartj\/ehm081","article-title":"Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25","volume":"28","author":"White","year":"2007","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B158","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.300.1.71","article-title":"Early invasive vs conservative treatment strategies in women and men with unstable angina and non\u2013ST-segment elevation myocardial infarction: a meta-analysis","volume":"300","author":"O\u2019Donoghue","year":"2008","journal-title":"JAMA"},{"key":"2024121216125244600_ehac515-B159","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/j.jacc.2010.03.007","article-title":"Long-term outcome of a routine versus selective invasive strategy in patients with non\u2013ST-segment elevation acute coronary syndrome","volume":"55","author":"Fox","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B160","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(20)30930-2","article-title":"Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data","volume":"396","author":"Kaura","year":"2020","journal-title":"Lancet"},{"issue":"Suppl 2","key":"2024121216125244600_ehac515-B161","first-page":"S154","article-title":"A comparison of outcomes between percutaneous coronary intervention versus coronary artery bypass surgery in octogenarian patients","volume":"95","author":"Wongcharoenkiat","year":"2012","journal-title":"J Med Assoc Thai"},{"key":"2024121216125244600_ehac515-B162","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ccd.26927","article-title":"Predictors of long-term outcomes after bypass grafting versus drug-eluting stent implantation for left main or multivessel coronary artery disease","volume":"90","author":"Chang","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B163","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamacardio.2017.2895","article-title":"Percutaneous coronary intervention vs coronary artery bypass grafting in patients with left main coronary artery stenosis: a systematic review and meta-analysis","volume":"2","author":"Giacoppo","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2024121216125244600_ehac515-B164","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/eurheartj\/ehn124","article-title":"Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: the global registry of acute coronary events","volume":"29","author":"Devlin","year":"2007","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/ehjcvp\/pvz031","article-title":"Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis","volume":"6","author":"Galli","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024121216125244600_ehac515-B166","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B167","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B168","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2215\/CJN.10471016","article-title":"Association of CKD with outcomes among patients undergoing transcatheter aortic valve implantation","volume":"12","author":"L\u00fcders","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024121216125244600_ehac515-B169","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.jcin.2018.04.016","article-title":"Arrhythmic burden as determined by ambulatory continuous cardiac monitoring in patients with new-onset persistent left bundle branch block following transcatheter aortic valve replacement","volume":"11","author":"Rod\u00e9s-Cabau","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B170","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacc.2019.06.012","article-title":"Coronary artery disease and transcatheter aortic valve replacement","volume":"74","author":"Faroux","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B171","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.amjcard.2018.07.025","article-title":"Comparison of outcomes of transfemoral versus transapical approach for transcatheter aortic valve implantation","volume":"122","author":"Kumar","year":"2018","journal-title":"Am J Cardiol"},{"key":"2024121216125244600_ehac515-B172","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"key":"2024121216125244600_ehac515-B173","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","article-title":"Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease","volume":"42","author":"ten Berg","year":"2021","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B174","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"},{"key":"2024121216125244600_ehac515-B175","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve","volume":"10","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B176","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jcin.2020.03.041","article-title":"Safety and efficacy of protamine administration for prevention of bleeding complications in patients undergoing TAVR","volume":"13","author":"Al-Kassou","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B177","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B178","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B179","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcin.2016.10.023","article-title":"Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement","volume":"10","author":"Seeger","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B180","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B181","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.jcin.2020.09.013","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR","volume":"13","author":"Kawashima","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B182","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B183","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B184","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B185","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1093\/eurheartj\/ehac139","article-title":"Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS","volume":"43","author":"Andreotti","year":"2022","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B186","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/europace\/eux254","article-title":"Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey","volume":"19","author":"Tilz","year":"2017","journal-title":"Europace"},{"key":"2024121216125244600_ehac515-B187","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.recesp.2012.09.013","article-title":"Defining the role of left atrial appendage closure in atrial fibrillation","volume":"66","author":"Andreotti","year":"2013","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2024121216125244600_ehac515-B188","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ccd.25297","article-title":"Left atrial appendage occlusion in octogenarians: short-term and 1-year follow-up","volume":"83","author":"Gafoor","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"key":"2024121216125244600_ehac515-B189","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.amjcard.2015.10.024","article-title":"Comparison of efficacy and safety of left atrial appendage occlusion in patients aged &lt;75 to \u226575 years","volume":"117","author":"Freixa","year":"2016","journal-title":"Am J Cardiol"},{"key":"2024121216125244600_ehac515-B190","first-page":"590","article-title":"Left atrial appendage occluder implantation for stroke prevention in elderly patients with atrial fibrillation: acute and long-term results","volume":"14","author":"Davtyan","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"2024121216125244600_ehac515-B191","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacep.2018.09.007","article-title":"Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion","volume":"4","author":"Alkhouli","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"2024121216125244600_ehac515-B192","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/j.jacc.2020.08.089","article-title":"Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials","volume":"76","author":"Turagam","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B193","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"Whitlock","year":"2021","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B194","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4244\/EIJY19M08_01","article-title":"EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion\u2014an update","volume":"15","author":"Glikson","year":"2020","journal-title":"EuroIntervention"},{"key":"2024121216125244600_ehac515-B195","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/bja\/aer274","article-title":"Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial","volume":"107","author":"Mantz","year":"2011","journal-title":"Br J Anaesth"},{"key":"2024121216125244600_ehac515-B196","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJMoa1401105","article-title":"Aspirin in patients undergoing noncardiac surgery","volume":"370","author":"Devereaux","year":"2014","journal-title":"N Engl J Med"},{"key":"2024121216125244600_ehac515-B197","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijcard.2017.12.088","article-title":"Perioperative aspirin therapy in non-cardiac surgery: a systematic review and meta-analysis of randomized controlled trials","volume":"258","author":"Wolff","year":"2018","journal-title":"Int J Cardiol"},{"key":"2024121216125244600_ehac515-B198","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamacardio.2016.3028","article-title":"Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting","volume":"1","author":"Gherli","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2024121216125244600_ehac515-B199","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ejcts\/ezx314","article-title":"2017 EACTS guidelines on perioperative medication in adult cardiac surgery","volume":"53","author":"Sousa-Uva","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"2024121216125244600_ehac515-B200","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","article-title":"2014 ESC\/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)","volume":"35","author":"Kristensen","year":"2014","journal-title":"Eur Heart J"},{"key":"2024121216125244600_ehac515-B201","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7326\/M17-2341","article-title":"Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery","volume":"168","author":"Graham","year":"2018","journal-title":"Ann Intern Med"},{"key":"2024121216125244600_ehac515-B202","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1016\/j.jacc.2016.09.959","article-title":"A bridging protocol in high-thrombotic risk mechanical valve bearers undergoing surgery or invasive procedures","volume":"68","author":"Denas","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024121216125244600_ehac515-B203","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2024121216125244600_ehac515-B204","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3390\/jcm10081755","article-title":"Precision phenomapping of acute coronary syndromes to improve patient outcomes","volume":"10","author":"Andreotti","year":"2021","journal-title":"J Clin Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/4\/262\/60925910\/ehac515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/4\/262\/60925910\/ehac515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T11:13:44Z","timestamp":1734002024000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/4\/262\/6881548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":204,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,7]]},"published-print":{"date-parts":[[2023,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac515","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,21]]},"published":{"date-parts":[[2022,12,7]]}}}